Fascinating presentation about ICI myocarditis by our Principal Investigator, @salimhayek featuring paper published by our postdoc, @Avasbind in JACC!

Here's what's new at the Hayek Lab: Welcome our two newcomers, Christina Hutten, PhD (postdoc), and Chris Adam (undergraduate research assistant). We're happy to have you! #GoBlue #CardiacLab

@umichmedicine is hosting a Medical Assistant Interview day at @UMich! Interview spots can be reserved at buff.ly/3C0VdGS

Just managing to submit a PCORI grant is worth a celebration. Hopefully we'll be celebrating again in 6 months when funding is determined! @salimhayek – at Ann Arbor, MI

Always fun to watch the team talent outside of the lab! capcut.com/watch/default-too… – at Ann Arbor, MI

13/19 Treatment strategies for cardiac metastasis: immunotherapy, targeted therapy, radiation, and surgery. Treatment w/ immunotherapy was more common in RCS vs. SR (65% vs. 25%), whereas surgical intervention was used more often in our systematic review (55% vs 15%). Figure 2D.

11/19 Mortality at 1-year post-diagnosis of cardiac metastasis was 35%, with 57% of patients having died at two years. The median survival time for patients with cardiac metastasis was 1.2 years compared with 4.4 years for patients without cardiac metastasis. Figure 4.

10/19 Figure 3. A total of 11 (48%) patients experienced at least one cardiovascular complication within one year after the diagnosis of cardiac metastasis with the most common being arrhythmia (30%), heart failure (22%), and pericardial effusion (17%).

8/19 Figure 2C. In the cohort study, cardiac metastasis commonly presented as a single cardiac mass (65%) in the right ventricle (65%), left ventricle (35%), or right atrium (35%).

7/19 Figure 2A, B. In the cohort study, the majority (61%) of patients had at least one symptom at the time of diagnosis of cardiac metastasis, the most common presenting symptoms being fatigue (35%) and dyspnea (30%). The most common physical exam finding was tachycardia (24.2%)